论文部分内容阅读
视网膜色素变性(RP)是一种可致盲的遗传性眼病,目前尚无有效的治疗措施.尽管近年来基因治疗、干细胞疗法、光遗传学、视网膜假体等新兴技术蓬勃发展,但短期内这些新技术尚未能广泛地应用于临床,故经典的药物疗法仍占据主要地位.虽然目前RP的致病机制暂未十分明确,但已有研究指出,光感受器细胞凋亡为RP形成的共同终末进程.近年来发现炎性因子的过度激活、活性氧自由基的形成可造成RP的进展,某些神经营养因子、光传导中重要物质的缺乏等也可进一步加重RP.药物治疗依据RP的共同致病途径,作用于RP形成的各个阶段,可广泛普适地应用于各种基因型的RP.本文分别从抗光感受器细胞凋亡、抗炎、抗氧化、营养神经等方面介绍近年来RP药物治疗的基础研究进展.“,”Retinitis pigmentosa (RP) is a hereditary ocular disease that can cause blindness.There is no effective treatment currently.Although new technologies,such as gene therapy,stem cell therapy,photogenetics and retinal prostheses have flourished in recent years,they have not been widely applied in clinical practice in the near future.Classical pharmacological treatment is the only choice for now.Although the mechanism of RP is not completely clear,researches have found that,photoreceptors apoptosis is the final common pathway in RP.Excessive inflammatory response,oxidative stress can influence RP process and cause retina degradation,and lack of neurotrophic factors and phototransduction associated molecules may also lead to RP exacerbation.According to the common pathological pathways of RP,pharmacological treatment can play its role widely and universally in different genotypes of RP on the above stages.This review provides an overview of the current basic researches of drug treatment from different respects,including anti-photoreceptors apoptosis,anti-inflammatory,anti-oxidation and neuro protection.